Menu
Recruiting NCT07331285

Bi-lateral HGN Therapy in Real-World Patients -Post Approval Research Investigation

— Observational Obstructive Sleep Apnea

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: This is a single arm study, all consented and eligible subjects will be implanted with the Genio® System 2.1.
Who it may be relevant to
Registry conditions: Obstructive Sleep Apnea. Basic parameters: from 22 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

The objective of the BREATHE study is to demonstrate the continued safety and effectiveness of the Genio® System in treating subjects diagnosed with moderate to severe obstructive sleep apnea (OSA) who are intolerant to or failed/refused PAP treatments.

Detailed description

BREATHE is a multicenter, prospective, single-arm, post-approval study. Following a baseline visit and implantation of the Genio® System 2.1, subjects will be asked to return for a therapy activation visit at approximately 8 weeks post-implant surgery.

The subject will have follow-up visits at 6 months, 9 months, 12 months and every 6-months thereafter up to 5 years post-implant surgery. Additional visits (for device titration or other reasons) are per standard of care and at the Investigator's discretion. Endpoints will be assessed at 12, 24, 36, 48 and 60 months.

Interventions

  • Device This is a single arm study, all consented and eligible subjects will be implanted with the Genio® System 2.1
    Genio® System 2.1

Primary outcome measures

  • Change in Apnea Hypopnea Index (AHI4%) [Time frame: 12 months]
  • Change in Oxyhemoglobin Desaturation Index (ODI4%) [Time frame: 12 months]
  • Device related SAEs [Time frame: 12 months]
  • Device-related and procedure-related SAEs [Time frame: 12 months]
Secondary outcome measures (9)
  • Mean change in AHI4 [Time frame: Baseline to 5 years]
  • Mean change in ODI4 [Time frame: Baseline to 5 years]
  • % responders AHI4 [Time frame: 2 years through 5 years]
  • % responders ODI4 [Time frame: 2 years through 5 years]
  • Subject Satisfaction [Time frame: 1 year through 5 years]
  • Improvement in ESS [Time frame: 1 year through 5 years]
  • Change in health status [Time frame: 1 year through 5 years]
  • Clinician impression of change in Subject's health status [Time frame: 1 year through 5 years]
  • Device-related Serious Adverse Events [Time frame: 2 years through 5 years]

Eligibility criteria

Inclusion criteria

  • Have an apnea-hypopnea index (AHI) greater than or equal to 15 and less than or equal to 65, measured on a full-night PSG performed no earlier than 2 years prior to enrollment (AHI4 and ODI4 available).
  • Be adults 22 years of age and older.
  • Have been confirmed to have failed, not tolerated, or be ineligible to be treated with current standard of care treatments for moderate to severe OSA.
  • Have pursued insurance pre-authorization for Genio® Therapy, recognizing that pre-authorization does not ensure payment, or demonstrate willingness to assume any out-of-pocket costs. The sponsor will not be responsible for treatment-related charges.
  • Agree to participate in the study and voluntarily sign and date an informed consent form.
  • Be willing and capable of complying with all study requirements, including specific lifestyle considerations, performing all follow-up visits, evaluation procedures and questionnaires for the whole duration of the trial.
  • Have a result of a Drug- Induced Sleep Endoscopy (DISE), no earlier than 2 years prior to enrollment.

Exclusion criteria

  • Combined central and mixed apnea-hypopnea index (AHI) greater than or equal to 25% of the total AHI.
  • Any functional or structural problem, medical illness or condition that would prevent or interfere with implantation, activation or continued use of the Genio® Therapy.
  • Have an implantable device which may be susceptible to unintended interaction with the Genio® System 2.1.
  • Women who are pregnant, planning to become pregnant or breastfeeding.
  • Any condition or procedure that has compromised neurological control of the upper airway.
  • Be part of the populations for which the safety and effectiveness of the Genio® System 2.1 has not been fully assessed:
  • Patients below 22 or above 75 years of age.
  • Patients with a Body Mass Index (BMI) above 32 kg/m2.
  • Patients with an Apnea Hypopnea Index (AHI) below 15 or over 65 events/hr.
  • Patients with Complete Concentric Collapse (CCC) at the soft palate level.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

United States · 2 centers
  • PharmaDev Clinical Research Institute, LLC — Miami
  • Nyxoah, Inc — Summit

Publications

  • Woodson BT, Kent DT, Huntley C, Hancock MK, Van Daele DJ, Boon MS, Huntley TC, Mickelson S, Gillespie MB, Suurna MV, Kacker A, Roy A, MacKay S, Withrow KP, Dedhia RC, Huyett P, Heiser C, Nicola SD, Makori F, Vanderveken OM, Padyha TA, Magalang UJ, Chio E, Kezirian EJ, Lewis R. Bilateral hypoglossal nerve stimulation for obstructive sleep apnea: a nonrandomized clinical trial. J Clin Sleep Med. 202 PMID 40702817

Identifiers

NCT: NCT07331285 · CL-BREATHE-2026

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗